selected scholarly activity
-
conferences
- FLCN variants and their role in parathyroid cancer and atypical parathyroid tumors. Cancer Research. 2024
- Abstract 5279: Molecular analysis of AMBRA1 as a candidate tumor suppressor in sporadic parathyroid adenomas. Cancer Research. 5279-5279. 2023
- MA 10.01 Durvalumab ± Tremelimumab with Platinum-Doublets in Non-Small Cell Lung Cancer: Canadian Cancer Trials Group Study IND.226. Journal of Thoracic Oncology. S1839-S1839. 2017
- Lung cancer chemotherapy agents induce protein disulphide isomerase dependent tissue factor decryption resulting in increased procoagulant activity in vitro and in vivo. Journal of Thrombosis and Haemostasis. 378-379. 2013
- A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29. Journal of Clinical Oncology. 2012
- Lung Cancer Chemotherapy Agents Increase Procoagulant Activity In Vitro and In Vivo. Blood. 19-20. 2011
- Funding academic oncology clinical trials.. Journal of Clinical Oncology. e16507-e16507. 2011
- Overall survival [OS] results of NCIC Clinical Trials Group [CTG] BR.24: a randomized, double-blind trial of carboplatin plus paclitaxel [C plus P] with either daily oral cediranib, a potent inhibitor of all vascular endothelial growth factor receptor tyrosine kinases, or placebo, in advanced non-small cell lung cancer [NSCLC]. Journal of Thoracic Oncology. S353-S353. 2009
- Priority health needs for patients receiving concurrent chemotherapy and radiation for stage III non-small cell lung cancer and impact of the role of the advanced practice nurse (APN). Journal of Thoracic Oncology. S436-S437. 2009
- Quality of life (QOL) outcomes with cediranib/placebo in combination with carboplatin/paclitaxel (CP) in advanced non-small cell lung cancer (ANSCLC): results from NCIC CTG BR.24. Journal of Thoracic Oncology. S288-S288. 2009
- Survival of patients with non small cell lung cancer (NSCLC) following diagnosis of brain metastases. Journal of Thoracic Oncology. S543-S544. 2009
- Hypertension (HTN) in National Cancer Institute of Canada Clinical Trials Group study BR.24: A randomized, double-blind phase II trial of carboplatin (C) and paclitaxel (P) with either daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo, in patients with advanced non-small cell lung cancer. Journal of Clinical Oncology. 2009
- Treatment and outcome of patients with brain metastases from non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2009
- CFD ANALYSIS OF BATCH-TYPE REHEATING FURNACE WITH REGENERATIVE BURNERS. HT2008: PROCEEDING OF THE ASME SUMMER HEAT TRANSFER CONFERENCE, VOL 3. 225-234. 2009
- RANDOMIZED, DOUBLE-BLIND PHASE II TRIAL OF CARBOPLATIN plus PACLITAXEL [C plus P] WITH EITHER DAILY ORAL CEDIRANIB, AN INHIBITOR OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR [VEGFR] TYROSINE KINASES, OR PLACEBO, IN ADVANCED NON-SMALL CELL LUNG CANCER [NSCLC]: A STUDY OF THE NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP. Annals of Oncology. 90-91. 2008
- Anticoagulation and bleeding: A pooled analysis of lung cancer trials of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. 8065-8065. 2008
- CFD ANALYSIS OF BATCH-TYPE REHEATING FURNACE FOR IMPROVED HEATING PERFORMANCE. IMECE 2008: PROCEEDINGS OF THE ASME INTERNATIONAL MECHANICAL ENGINEERING CONGRESS AND EXPOSITION, VOL 3. 139-148. 2008
- CFD analysis of batch-type reheating furnace. PROCEEDINGS OF THE ASME INTERNATIONAL MECHANICAL ENGINEERING CONGRESS AND EXPOSITION 2007, VOL 6. 753-759. 2008
- How compliant are patients with oral hormonal therapies? Data from a randomized, placebo controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (NCIC CTG MA.12). Breast Cancer Research and Treatment. S144-S144. 2007
- Causality assessment of adverse events in oncology clinical trials: A qualitative study. Pharmacoepidemiology and Drug Safety. S181-S181. 2007
- Development and validation of an adverse event causality assessment tool for use in oncology clinical trials. Pharmacoepidemiology and Drug Safety. S180-S181. 2007
- PD3-2-7: Implications of tumour cavitation on response assessment in trials of Vascular Endothelial Growth Factor Receptor (VEGFR) Inhibitors in combination with platinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): An analysis of trials conducted by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG).. Journal of Thoracic Oncology. S465-S465. 2007
- A tool for assessing adverse events in phase I/II oncology clinical trials. Journal of Clinical Oncology. 2007
- Tamoxifen (T) compared to placebo (P), after adjuvant chemotherapy (CT), in premenopausal women with early breast cancer (EBC): Interim results of NCIC-CTG MA.12. Journal of Clinical Oncology. 2007
- Effects of AZD2171 on pharmacokinetics (PK) of carboplatin (C) and paclitaxel (P) in patients with advanced non-small cell lung cancer (NSCLC): a study of the National Cancer Institute of Canada Clinical Trials Group. European Journal of Cancer, Supplement. 32-32. 2006
- Delays in diagnosis and initiating treatment for patients with lung cancer.. Journal of Clinical Oncology. 326S-326S. 2006
- Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors (VEGFR), in combination with carboplatin (C) plus paclitaxel (T) in patients with advanced non-small cell lung cancer (NSCLC): A study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG).. Journal of Clinical Oncology. 134S-134S. 2006
- Optimizing the design and distribution of clinical trial information via handheld devices.. Journal of Clinical Oncology. 336S-336S. 2006
- Loss of heterozygosity analysis of parathyroid adenomas by single nucleotide polymorphism arrays. Cancer Research. 2006
- Phase I study of daily oral AZD 2171, an inhibitor of the vascular endothelial growth factor receptor (VEGFR), in combination with carboplatin/paclitaxel in patients with advanced non-small cell lung cancer (NSCLC): A study of the NCICCTG.. Clinical Cancer Research. 8970S-8970S. 2005
- P-936 Use of an algorithm to aid determination of causality in early clinical trials of lung cancer using targeted therapy. Lung Cancer. S365-S365. 2005
- The effect of doxycycline on bone turnover and tumor markers in breast cancer (BC) patients with skeletal metastases. Journal of Clinical Oncology. 3198-3198. 2005
- The effect of doxycycline on bone turnover and tumor markers in breast cancer (BC) patients with skeletal metastases.. Journal of Clinical Oncology. 240S-240S. 2005
- Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG BR. 18.. Journal of Clinical Oncology. 626S-626S. 2004
- Pharmacologic insights into the future of trastuzumab.. Annals of Oncology. 43-47. 2001
- The BEST study - A Canadian multicenter randomized trial of group psychosocial support in metastatic breast cancer. Early results.. Psycho-Oncology. S43-S43. 2000
- Offering a choice between two adjuvant chemotherapy regimens: a pilot study to develop a decision aid for women with breast cancer. Patient Education and Counseling. 283-291. 1999
- A DOUBLE-BLIND RANDOMIZED TRIAL OF MINI-DOSE WARFARIN FOR THE PREVENTION OF THROMBOEMBOLISM (TE) IN PATIENTS WITH STAGE-IV BREAST-CANCER. Thrombosis and Haemostasis. 981-981. 1993
- Monitoring compliance and contamination in a chemoprevention trial. Contemporary Clinical Trials. 353-354. 1989
- A RANDOMIZED TRIAL COMPARING 12 WEEKS WITH 36 WEEKS OF ADJUVANT CHEMOTHERAPY IN STAGE-II BREAST-CANCER. Breast Cancer Research and Treatment. 144-144. 1988
- CANCER-CHEMOTHERAPY AND THROMBOSIS. Thrombosis and Haemostasis. 114-114. 1987
- CANCER-CHEMOTHERAPY AND THROMBOSIS. Breast Cancer Research and Treatment. 122-122. 1987
- QUALITY-OF-LIFE IN BREAST-CANCER - AN INSTRUMENT FOR CLINICAL-TRIALS. Clinical and Investigative Medicine. A47-A47. 1986
- QUALITY-OF-LIFE IN STAGE-II BREAST-CANCER - AN INSTRUMENT FOR CLINICAL-TRIALS. Breast Cancer Research and Treatment. 102-102. 1986
- QUALITY OF LIFE (QL) IN STAGE-2 BREAST-CANCER - USE OF THE TIME TRADE-OFF (TTO) METHOD. Clinical and Investigative Medicine. A87-A87. 1985
-
journal articles
- Trimaran Preliminary Structural Design Procedures for a Large High Speed Sealift Ship. NAVAL ENGINEERS JOURNAL. 129:113-121. 2017
- Distributed Cognition and Process Management Enabling Individualized Translational Research: The NIH Undiagnosed Diseases Program Experience.. Frontiers in Medicine. 3:39. 2016
- Lung cancer chemotherapy agents increase procoagulant activity via protein disulfide isomerase-dependent tissue factor decryption. Blood Coagulation and Fibrinolysis. 26:36-45. 2015
- Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. European Journal of Cancer. 50:706-712. 2014
- Survival of Patients with Non-Small-Cell Lung Cancer after a Diagnosis of Brain Metastases. Current Oncology. 20:300-306. 2013
- A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29.. Journal of Clinical Oncology. 30:7511-7511. 2012
- Funding Oncology Clinical Trials: Are Cooperative Group Trials Sustainable?. Journal of Clinical Oncology. 30:1456-1461. 2012
- A qualitative study evaluating causality attribution for serious adverse events during early phase oncology clinical trials. Investigational New Drugs. 29:1013-1020. 2011
- Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. Annals of Oncology. 21:2220-2226. 2010
- A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12). Annals of Oncology. 21:283-290. 2010
- Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study. Journal of Clinical Oncology. 28:49-55. 2010
- Hypertension (HTN) in National Cancer Institute of Canada Clinical Trials Group study BR.24: A randomized, double-blind phase II trial of carboplatin (C) and paclitaxel (P) with either daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo, in patients with advanced non-small cell lung cancer. Journal of Clinical Oncology. 27:3527-3527. 2009
- Anticoagulation and Bleeding: A Pooled Analysis of Lung Cancer Trials of the NCIC Clinical Trials Group. Journal of Thoracic Oncology. 4:586-594. 2009
- Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 27:404-410. 2009
- Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. 26:1871-1878. 2008
- Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. Journal of Clinical Oncology. 25:4278-4284. 2007
- A tool for assessing adverse events in phase I/II oncology clinical trials. Journal of Clinical Oncology. 25:6518-6518. 2007
- Randomized phase II study of maintenance vandetanib (ZD6474) in small cell lung cancer (SCLC) patients who have a complete or partial response to induction therapy: NCIC CTG BR.20. Journal of Clinical Oncology. 25:7522-7522. 2007
- Tamoxifen (T) compared to placebo (P), after adjuvant chemotherapy (CT), in premenopausal women with early breast cancer (EBC): Interim results of NCIC-CTG MA.12. Journal of Clinical Oncology. 25:547-547. 2007
- Absence of Stabilizing Mutations of β-Catenin Encoded by CTNNB1 Exon 3 in a Large Series of Sporadic Parathyroid Adenomas. Journal of Clinical Endocrinology and Metabolism (JCEM). 92:1564-1566. 2007
- Delays in diagnosis and initiating treatment for patients with lung cancer. Journal of Clinical Oncology. 24:6102-6102. 2006
- Final results of a phase I study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor receptors (VEGFR), in combination with carboplatin (C) + paclitaxel (T) in patients with advanced non-small cell lung cancer (NSCLC): A study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). Journal of Clinical Oncology. 24:3054-3054. 2006
- Phase II Study of Troxacitabine (BCH-4556) in Patients with Advanced Non-Small-Cell Lung Cancer. Lung. 183:265-272. 2005
- Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. Journal of Clinical Oncology. 23:2831-2839. 2005
- Effects of Long-term Vitamin E Supplementation on Cardiovascular Events and Cancer. Journal of the American Medical Association (JAMA). 293:1338-1338. 2005
- Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. Lung Cancer. 46:361-368. 2004
- Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG BR.18. Journal of Clinical Oncology. 22:7038-7038. 2004
- Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG BR.18. Journal of Clinical Oncology. 22:7038-7038. 2004
- Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression. Journal of Clinical Oncology. 22:1063-1070. 2004
- Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel. Journal of Clinical Oncology. 21:3965-3971. 2003
- Quality of Life in a Randomized Trial of Group Psychosocial Support in Metastatic Breast Cancer: Overall Effects of the Intervention and an Exploration of Missing Data. Journal of Clinical Oncology. 21:1944-1951. 2003
- The Effect of Group Psychosocial Support on Survival in Metastatic Breast Cancer. New England Journal of Medicine. 345:1719-1726. 2001
- Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma. Cancer. 92:595-600. 2001
- Randomised phase II study of BMS-275291 versus placebo in patients (pts) with stage IIIb or IV non small cell lung cancer (NSCLC) receiving paclitaxel + carboplatin (PC): National Cancer Institute of Canada clinical trials group (NCIC CTG) br.18. European Journal of Cancer. 37:S19-S20. 2001
- A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours. Annals of Oncology. 11:1579-1584. 2000
- Phase II trial of MTA (AlimtaTM) and cisplatin in patients with advanced Non-Small Cell Lung Cancer (NSCLC). Lung Cancer. 29:13-13. 2000
- Lessons learned from enrollment in the BEST study—A multicenter, randomized trial of group psychosocial support in metastatic breast cancer. Journal of Clinical Epidemiology. 53:47-55. 2000
- Phase II Trial of N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and Doxorubicin Chemotherapy in Metastatic Breast Cancer: A National Cancer Institute of Canada Clinical Trials Group Study. Journal of Clinical Oncology. 17:3431-3437. 1999
- Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. Journal of Clinical Oncology. 16:2651-2658. 1998
- Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.. Journal of Clinical Oncology. 16:2651-2658. 1998
- A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer. European Journal of Cancer. 34:1008-1014. 1998
- The supportive care needs of newly diagnosed cancer patients attending a regional cancer center. Cancer. 80:1518-1524. 1997
- 234 Importance of timing for thoracic irradiation (TI) in the combined modality treatment of limited-stage small-cell lung cancer (LSCLC): An update of the National Cancer Institute of Canada (NCIC) BR6 study. Lung Cancer. 18:61-61. 1997
- Moving promising research findings to the clinic: Methodological issues in the design and conduct of clinical trials of retinoids. International Journal of Cancer. 70:467-469. 1997
- Retinoids and Lung Cancer. Advances in Organ Biology. 3:261-287. 1997
- Randomized trial of group psychosocial support in metastatic breast cancer: the BEST study. Cancer Treatment Reviews. 22:91-96. 1996
- RECAPITULATION OF A NORMAL CELLULAR GROWTH PROGRAM IN EARLY INVASIVE BREAST-CANCER. International Journal of Oncology. 7:311-318. 1995
- The arotinoids: early clinical experience and discussion of future development.. Leukemia. 8:1817-1824. 1994
- Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors.. Leukemia. 8:1622-1625. 1994
- Financial Concerns Prompt Sponsoring Pharmaceutical Company to Halt International Phase I Studies. Journal of the National Cancer Institute. 86:1353-1353. 1994
- Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. The Lancet. 343:886-889. 1994
- Phase II Trial of 13-cis-Retinoic Acid Plus Interferon in Non-Small-Cell Lung Cancer: For the National Cancer Instit ute of Canada Clinical Trials Group. Journal of the National Cancer Institute. 86:306-309. 1994
- Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors.. Leukemia. 8 Suppl 3:S38-S41. 1994
- Patterns of failure following loco-regional radiotherapy in the treatment of limited stage small cell lung cancer. International Journal of Radiation Oncology Biology Physics. 28:355-362. 1994
- The arotinoids: early clinical experience and discussion of future development.. Leukemia. 8 Suppl 3:S42-S49. 1994
- Tamoxifen and cancer of the endometrium.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 148:2113-2114. 1993
- Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.. Journal of Clinical Oncology. 11:336-344. 1993
- A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. European Journal of Cancer. 29:37-43. 1993
- Chemotherapy induced amenorrhoea in a randomised trial of adjuvant chemotherapy duration in breast cancer. European Journal of Cancer. 29:21-23. 1993
- The Canadian Experience with Intensive Fluorouracil, Epirubicin and Cyclophosphamide in Patients with Early Stage Breast Cancer. Drugs. 45:51-59. 1993
- The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial. British Journal of Cancer. 65:737-743. 1992
- The effect of systemic adjuvant chemotherapy on local breast recurrence in node positive breast cancer patients treated by lumpectomy without radiation. British Journal of Cancer. 65:130-132. 1992
- Toxic megacolon associated with anticancer chemotherapy.. Canadian Journal of Surgery. 34:339-341. 1991
- Optimal thoracic irradiation (TI) in the treatment of limited stage small cell lung cancer (LSCLC). International Journal of Radiation Oncology Biology Physics. 21:138-138. 1991
- A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer.. Journal of Clinical Oncology. 8:1217-1225. 1990
- Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer a phase I/II study. Cancer. 65:1895-1902. 1990
- Use of screening phase data to evaluate observer variation of sputum cytodiagnosis as an outcome measure in a chemoprevention trial.. Cancer Research. 50:1216-1219. 1990
- Chemoprevention for lung cancer--evidence for a high degree of compliance.. Cancer Epidemiology. 14:521-525. 1990
- Recruitment for an efficacy study in chemoprevention—The concerned smoker study. Preventive Medicine. 18:700-710. 1989
- Etretinate Blood Levels in Monitoring of Compliance and Contamination in a Chemoprevention Trial. Journal of the National Cancer Institute. 81:795-798. 1989
- Quality of life in stage II breast cancer: an instrument for clinical trials.. Journal of Clinical Oncology. 6:1798-1810. 1988
- Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.. Journal of Clinical Oncology. 6:633-641. 1988
- The Thrombogenic Effect of Anticancer Drug Therapy in Women with Stage II Breast Cancer. New England Journal of Medicine. 318:404-407. 1988
- Phase II study of high dose weekly intravenous human lymphoblastoid interferon in renal cell carcinoma. British Journal of Cancer. 55:541-542. 1987
- ACUTE VINCRISTINE NEUROTOXICITY. The Lancet. 325:346-346. 1985
- Combination chemotherapy using high or low dose methotrexate for small cell carcinoma of the lung — A randomised trial. Medical Oncology. 1:9-14. 1984
- Late recurrence in Hodgkin's disease: A report of two cases. Pediatric Blood and Cancer. 12:148-149. 1984
- Retinoblastoma, eosinophilic granuloma, and malignant melanoma: A case report. Pediatric Blood and Cancer. 12:347-348. 1984
- Epileptic Seizures Associated With Cisplatin Administration. Investigative Urology. 130:405-405. 1983
- Epileptic seizures associated with cisplatin administration.. Journal of the National Cancer Institute. 66:1719-1722. 1982
- Chemotherapy of advanced ovarian carcinoma: Initial experience using a platinum-based combination. Cancer. 49:1778-1783. 1982
- Interaction of VP16-213 with the DNA repair antagonist chloroquine. Cancer Chemotherapy and Pharmacology. 7:123-126. 1982
- ETOPOSIDE: A NEW ANTI-CANCER AGENT. The Lancet. 318:912-915. 1981
- Response of siadh to chemotherapy in small cell carcinoma. Proceedings of the American Association for Cancer Research. Vol. 22. 1981
- SMALL-CELL LUNG CANCER. The Lancet. 315:252-252. 1980
- Podophyllotoxin derivative VP 16-213. Cancer Chemotherapy and Pharmacology. 3:71-80. 1979
- Drug-induced peripheral neuropathies.. The BMJ. 1:955-955. 1979
- Small-cell lung cancer: A curable disease?. Respiratory Medicine. 73:327-348. 1979